Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Revenue (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Revenue for 3 consecutive years, with $1.1 million as the latest value for Q2 2024.

  • Quarterly Revenue fell 85.86% to $1.1 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2025, down 92.95% year-over-year, with the annual reading at $1.9 million for FY2024, 90.55% down from the prior year.
  • Revenue for Q2 2024 was $1.1 million at Werewolf Therapeutics, up from $742000.0 in the prior quarter.
  • The five-year high for Revenue was $8.1 million in Q2 2023, with the low at $742000.0 in Q1 2024.
  • Average Revenue over 3 years is $4.2 million, with a median of $4.5 million recorded in 2023.
  • The sharpest move saw Revenue soared 94.82% in 2023, then tumbled 85.86% in 2024.
  • Over 3 years, Revenue stood at $7.3 million in 2022, then tumbled by 79.39% to $1.5 million in 2023, then dropped by 23.85% to $1.1 million in 2024.
  • According to Business Quant data, Revenue over the past three periods came in at $1.1 million, $742000.0, and $1.5 million for Q2 2024, Q1 2024, and Q4 2023 respectively.